Cardiva Medical Appoints Jeri Hilleman to the Company’s Board of Directors
SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl (“Jeri”) Hilleman to the company’s Board of Directors.
We are thrilled to welcome Jeri to our team and look forward to leveraging her deep expertise with high-growth medical device companies and in building global markets for innovative technologies,” said John Russell, president and CEO of Cardiva Medical, Inc. “We believe that Jeri’s dynamic experience will help strengthen our position as a leader in vessel closure for coronary, peripheral and electrophysiology procedures as we continue to accelerate Cardiva’s exciting growth.”
Ms. Hilleman currently serves on the board of directors and as audit committee chair of Novocure (Nasdaq: NVCR), Minerva (Nasdaq: NERV) and SI-Bone (Nasdaq: SIBN). She most recently served as chief financial officer of Intersect ENT (Nasdaq: XENT).
“Cardiva Medical has emerged as a leader in vascular closure,” said Hilleman. “I look forward to working with the Cardiva Board and leadership team to expand the reach of Cardiva’s portfolio of vascular closure devices to even more patients, physicians and health systems.”
About Cardiva Medical, Inc.
Cardiva Medical, Inc. is a privately held medical device company focused on transforming vascular closure for the benefit of patients, hospitals and physicians in the over 5.5 million catheter-based coronary, peripheral and electrophysiology procedures in the United States that require access site closure each year.
The Company’s VASCADE® vascular closure system has been PMA-approved by the FDA since 2013 and is indicated for vessel closure following 5-7F arterial and venous procedures. VASCADE® is the only marketed closure system to demonstrate a statistically significant reduction in access site complications compared to the existing standard of care in a prospective, randomized, controlled clinical trial called RESPECT. The latest product in the Company’s portfolio is VASCADE® MVP Venous Vascular Closure System, the only marketed vessel closure technology designed specifically for Electrophysiology procedures – and clinically proven by Electrophysiology physicians in a multi-center, randomized, controlled clinical trial called AMBULATE. VASCADE® MVP received PMA approval in late 2018.
Cardiva has won numerous recent awards for clinical, commercial and operational excellence – including the Shingo Bronze Medallion. The Company is headquartered in Santa Clara, California.
For further information, visit our website at www.cardivamedical.com. VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical®, Inc.